<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02929901</url>
  </required_header>
  <id_info>
    <org_study_id>147</org_study_id>
    <nct_id>NCT02929901</nct_id>
  </id_info>
  <brief_title>The Effects of Coffee Main Constituents (Caffeine and Chlorogenic Acid) Supplementation on Inflammatory, Metabolic Factors, Hepatic Steatosis and Fibrosis in None- Alcoholic Fatty Liver Patients With Type 2 Diabetes</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Nutrition and Food Technology Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Nutrition and Food Technology Institute</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effects of coffee main constituents (caffeine
      and chlorogenic acid) supplements on inflammatory, metabolic factors, hepatic steatosis and
      fibrosis in none- alcoholic fatty liver patients with type 2 diabetes. Two hundred patients
      with fatty liver and type 2 diabetes will be randomly assigned to one of four groups: group
      1, caffeine (200 mg/d) plus chlorogenic acid (200 mg/d); group 2, caffeine (200 mg/d) plus
      placebo; group 3, chlorogenic acid (200 mg/d) plus placebo; group 4, placebo plus placebo.
      Supplementation will be daily and will supervise for 6 months.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hepatic steatosis</measure>
    <time_frame>6 months</time_frame>
    <description>measured by CAP score using Fibroscan</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glucose</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycated hemoglobin (HBA1C)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>alanine aminotransferase (ALT)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>aspartate aminotransferase (ALS)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High sensitive C reactive protein ( hs- CRP)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Type 2 Diabetes Nonalcoholic Fatty Liver</condition>
  <arm_group>
    <arm_group_label>caffeine and chlorogeinc acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>caffeine (200 mg) 1 capsule / day for 6 months plus chlorogenic acid (200 mg) 1 capsule / day for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>caffeine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>caffeine (200 mg) 1 capsule / day for 6 months plus placebo (200) mg 1 capsule / day for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>chlorogenic acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>chlorogenic acid (200 mg) 1 capsule / day for 6 months plus placebo (200 mg) 1 capsule / day for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo (200 mg) 1 capsule / day for 6 months plus placebo (200 mg) 1 capsule / day for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>caffeine and chlorogenic acid</intervention_name>
    <description>caffeine plus chlorogenic acid</description>
    <arm_group_label>caffeine and chlorogeinc acid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>caffeine</intervention_name>
    <description>caffeine plus placebo</description>
    <arm_group_label>caffeine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>chlorogenic acid</intervention_name>
    <description>chlorogenic acid plus placebo</description>
    <arm_group_label>chlorogenic acid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo plus placebo</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient diagnosed with type 2 diabetes based on American Diabetes Association (ADA)
             definition or who only take oral antidiabetic drug.

          -  CAPscore &gt;263

        Exclusion Criteria:

          -  Criteria:

               -  Taking any kind of antibiotics two weeks before recruitment;

               -  History of alcohol consumption ;

               -  pregnancy or lactation;

               -  Professional athletes;

               -  Other liver disease (viral/etc);

               -  High dose synthetic estrogens, methotrexate , amiodarone, steroids, chloroquine,
                  immunosuppressive drugs;

               -  A history of Cardiovascular disease;

               -  Renal disease, Celiac disease, Cirrhosis;

               -  History of Upper Gastrointestinal surgery ;

               -  A history of hypothyroidism or Cushing's syndrome;

               -  History of drug dependence;

               -  Body mass index (BMI) ≥35 kg/m2;

               -  A restrictive diet or weight change ≥ 5 kg during the 3 months prior to study;

               -  Any change in treatment with oral hypoglycemic; anti hypertensive and antilipid
                  agents during the study;

               -  Use of weight loss medications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>NNFTRI clinic</name>
      <address>
        <city>Tehran</city>
        <zip>19435</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 9, 2016</study_first_submitted>
  <study_first_submitted_qc>October 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 11, 2016</study_first_posted>
  <last_update_submitted>October 14, 2016</last_update_submitted>
  <last_update_submitted_qc>October 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Nutrition and Food Technology Institute</investigator_affiliation>
    <investigator_full_name>Dr Azita Hekmatdoost</investigator_full_name>
    <investigator_title>Dr Azita Hekmatdoost</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Caffeine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

